12:00 AM
 | 
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ATX-101: Completed Phase III enrollment

Kythera completed enrollment of a total of more than 1,000 patients in the identical, double-blind, placebo-controlled, North American Phase III REFINE-1 and REFINE-2 trials evaluating 2 mg/cm 2 subcutaneous ATX-101 in 28-day cycles for up to 6 cycles.

In April,...

Read the full 181 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >